Apr 28, 2021 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update
Apr 13, 2021 7:00am EDT Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Mar 11, 2021 7:30am EST Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
Mar 02, 2021 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 23, 2021 7:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update
Feb 18, 2021 6:30am EST Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Jan 29, 2021 2:45pm EST Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
